GENOMIC TEST FOR PAEDIATRIC CANCER

imegen

Reliability in genetics

PAEDIATRIC CANCER PANEL

Childhood and adult tumours are very different and therefore, the way to approach them should be adapted to each malignancy. To this end, Imegen has developed a specific solution to help in the clinical care of paediatric cancer patients. This panel is a comprehensive molecular diagnostic test that interrogates all the genomic regions with relevant clinical utility in the diagnostic, prognostic and therapeutic landscapes. It is indicated for primary tumours, recurring and follow-up of patients.

Clinical utility:

- To analise the tumour before the first-line treatment to know somatic mutations related to prognosis and possible therapies, also considering the relevant variants in pharmacogenomics.
- To diagnose recurring cases analysing *de novo* tumour alterations that could change the therapeutic strategy.
- To detect those pathogenic and likely pathogenic germline variants acquired by the patient during his development or inherited from his parents. Genetic counselling is available if needed.

Technical features:

- **Complete sequencing of 255 genes** associated with paediatric tumours, including *driver* genes.
- Analysis of **SNVs** (somatic mutations and SNPs) and **CNVs** (copy-number gain from one copy to gene amplification and deletions).
- Identification of **somatic and germline** mutations.
- Available for **FFPE, frozen samples and cell lines.**
- **Analysis of gene fusions**, with particular focus on those that are actionable in adults and those in validation stage for paediatric patients.
- Detection of **microsatellite instability** with direct implications in immunotherapy treatments.

onco genomics
by imegen